Author

Zena Komrokji

Observed name: Zena R Komrokji

Observed institution: Moffitt Cancer Center

ORCID: 0009-0004-0093-533X

Observed ORCID: 0009-0004-0093-533X

OpenAlex ID: A5115007065

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL

2024 · Diane Habib, Hagop M. Kantarjian, et al. · Blood · 5

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

2024 · Rami S. Komrokji, Zena Komrokji, et al. · Blood · 5

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

2024 · Zhuoer Xie, Zena Komrokji, et al. · Blood · 5

PDF

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),

2025 · Zena Komrokji, Zena Komrokji, et al. · Leukemia Research · 3

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

2024 · Rami S. Komrokji, Najla H. Al Ali, et al. · Blood · 3

PDF

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

2024 · Jayastu Senapati, Hagop M. Kantarjian, et al. · Blood · 2

PDF

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

2024 · Rami S. Komrokji, Zena Komrokji, et al. · Blood · 1

Durable Complete Remission Represents Treatment-Responsive Biology Rather Than Baseline Disease Characteristics in Higher-Risk Myelodysplastic Syndromes

2026 · Najla Al Ali, Zena Komrokji, et al. · International Journal of Cancer Care and Delivery

PDF

POSTER: MDS-515: Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology

2026 · Julie Braish, Najla Al Ali, et al. · Clinical Lymphoma Myeloma & Leukemia

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms

2026 · Zhuoer Xie, Zena R Komrokji, et al. · Blood

Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment

2026 · Rami Komrokji, Zaker Schwabkey, et al. · Haematologica

PDF

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

2026 · Rami S. Komrokji, Zena Komrokji, et al. · Blood Neoplasia

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

2025 · Rami Komrokji, Najla Al Ali, et al. · Blood

PDF

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

2025 · Zena Komrokji, Najla Al Ali, et al. · Blood

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

2025 · Rami Komrokji, Amin Azem, et al. · Blood

PDF

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

2025 · Amy McLemore, Surendra Neupane, et al. · Blood

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

2025 · Julie Braish, Najla Al Ali, et al. · Blood

PDF

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

2025 · Roberta S. Azevedo, Tapan Kadia, et al. · Blood

PDF

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

2025 · Zhuoer Xie, Christy James, et al. · Blood

Mapping out the impact of MAP kinase in primary myelofibrosis

2025 · Samuel Reynolds, Andrew Kuykendall, et al. · Blood

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

2024 · Fadi G. Haddad, Hagop M. Kantarjian, et al. · Blood

Works count: 21

Citation count: 24

H-index: 3

I10-index: